COVID-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (COVID-19) in a 38-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 076C21A, 042l20a and 025l20a) for COVID-19 vaccination.     No specific Drug allergy was reported.  Concurrent medical conditions included Sleep apnea, Hypertension, Depression and Obesity. Concomitant products included BUPROPION, HYDROCHLOROTHIAZIDE, ATENOLOL, CITALOPRAM, LOSARTAN, METFORMIN, OMEPRAZOLE and SEMAGLUTIDE (RYBELSUS) for an unknown indication.   On 18-Jan-2021 at 2:00 PM, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 18-Feb-2021 at 1:00 PM, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 22-Oct-2021 at 9:00 AM, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 26-May-2022 to 31-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID-19) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 04-Jun-2022, SARS-CoV-2 test: positive (Positive) positive. On an unknown date, SARS-CoV-2 test: positive (Positive) positive.         On 03-Jun-2022 at 22:00, symptoms of the patient resumed (mild congestion). For this resumed symptoms, the patient did not receive any treatments.  Company comment: This spontaneous case concerns a 38-year-old male patient, with concurrent sleep apnea syndrome, hypertension, depression and obesity who experienced the unexpected non-serious adverse event of special interest COVID-19, which occurred at an unspecified date after receiving the third dose of mRNA1273. The patient was initially diagnosed with COVID-19 and was started with Nirmatrelvir/Ritonavir (Paxlovid) for 5 days. Patient experienced resumption of mild congestion 3 days post cessation of treatment and tested positive on the SARS-COV2-Test the following day. The patient's comorbidities of sleep apnea syndrome, hypertension, depression and obesity may be considered as risk factors for COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 38-year-old male patient, with concurrent sleep apnea syndrome, hypertension, depression and obesity who experienced the unexpected non-serious adverse event of special interest COVID-19, which occurred at an unspecified date after receiving the third dose of mRNA1273. The patient was initially diagnosed with COVID-19 and was started with Nirmatrelvir/Ritonavir (Paxlovid) for 5 days. Patient experienced resumption of mild congestion 3 days post cessation of treatment and tested positive on the SARS-COV2-Test the following day. The patient's comorbidities of sleep apnea syndrome, hypertension, depression and obesity may be considered as risk factors for COVID-19. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.